Propiopromazine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Propiopromazine
Accession Number
DB11540
Type
Small Molecule
Groups
Vet approved
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Propiopromazine hydrochlorideU0BND6SD2I7681-67-6ZFWVWZODBGTOIL-UHFFFAOYSA-N
Categories
UNII
Y1BCT334I7
CAS number
Not Available
Weight
Average: 340.49
Monoisotopic: 340.160934575
Chemical Formula
C20H24N2OS
InChI Key
ZQTVCQIJTREKSP-UHFFFAOYSA-N
InChI
InChI=1S/C20H24N2OS/c1-4-18(23)15-10-11-20-17(14-15)22(13-7-12-21(2)3)16-8-5-6-9-19(16)24-20/h5-6,8-11,14H,4,7,12-13H2,1-3H3
IUPAC Name
1-{10-[3-(dimethylamino)propyl]-10H-phenothiazin-2-yl}propan-1-one
SMILES
CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN(C)C)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2,5-Dimethoxy-4-ethylamphetaminePropiopromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetaminePropiopromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetaminePropiopromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Propiopromazine.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Propiopromazine.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Propiopromazine.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Propiopromazine.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Propiopromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Propiopromazine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Wheat JD: Penile paralysis in stallions given propiopromazine. J Am Vet Med Assoc. 1966 Feb 15;148(4):405-6. [PubMed:5950045]
  2. Olling M, Stephany RW, Rauws AG: The determination of propiopromazine in animal tissue. J Vet Pharmacol Ther. 1981 Dec;4(4):291-4. [PubMed:7349344]
  3. Haagsma N, Bathelt ER, Engelsma JW: Thin-layer chromatographic screening method for the tranquillizers azaperone, propiopromazine and carazolol in pig tissues. J Chromatogr. 1988 Jan 29;436(1):73-9. [PubMed:2897377]
  4. Wronska D, Niezgoda J, Pierzchala K, Sechman A, Bobek S, Hamid AB: [Effect of phenothiazine derivative on adrenal cortex response of sheep to repeated emotional stress]. Endokrynol Pol. 1991;42(4):567-74. [PubMed:1364508]
  5. Hofman WF, Riegle GD: Effects of electroanesthesia and a phenothiazine tranquilizer on thermoregulation in the sheep. Am J Vet Res. 1977 Mar;38(3):403-6. [PubMed:15489]
  6. Rauws AG: [Tranquilizers in the transport of slaughtering pigs: a problem of residues?]. Tijdschr Diergeneeskd. 1983 Sep 1;108(17):659-64. [PubMed:6138880]
  7. Garcia-Martinez D, Portilla-de Buen E, Leal C, Santillan P, Muniz J: The immediate response to severe shock in a canine model with a combination of hypertonic-hyperoncotic solution with naloxone. Shock. 2006 Oct;26(4):379-85. [PubMed:16980885]
  8. Patricolo M, Paolocci N, Zangari A, Antonica A, Rossi L, Magni F, Viola-Magni MP, Caione P, Lais A, Rivosecchi M: [Hepatic resection in the fetal rabbit. Histologic comparison of tissue regeneration in the fetus versus the adult]. Minerva Chir. 1996 Nov;51(11):971-7. [PubMed:9072727]
External Links
ChemSpider
22768
BindingDB
50408509
ChEMBL
CHEMBL41169

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00538 mg/mLALOGPS
logP4.74ALOGPS
logP4.19ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)16.64ChemAxon
pKa (Strongest Basic)8.5ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area23.55 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity103.98 m3·mol-1ChemAxon
Polarizability39.6 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / Aryl alkyl ketones / Benzenoids / 1,4-thiazines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / Aryl alkyl ketone / Aryl ketone / Para-thiazine / Benzenoid / Ketone
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on February 26, 2016 10:39 / Updated on September 02, 2019 21:53